Peng Yi, Chen Lu, Ye Sheng, Kang Yu, Liu Junqing, Zeng Su, Yu Lushan
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
The Children's Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China.
Asian J Pharm Sci. 2020 Mar;15(2):220-236. doi: 10.1016/j.ajps.2020.02.004. Epub 2020 Mar 4.
In recent years, the continuous occurrence of multi-drug resistance in the clinic has made people pay more attention to the transporter. Changes in the expression and activity of transporters can cause corresponding changes in drug pharmacokinetics and pharmacodynamics. The drug-drug interactions (DDI) caused by transporters can seriously affect drug effectiveness and toxicity. In the development of pharmaceutical preparations, people have increasingly concerned about the effects and regulation of transporters in drug effects. To improve the targeting and physicochemical properties of drugs, the development of targeted agents is very rapid. Among them, novel nano-formulations are the best. With the continuous innovation and development of nano-formulation, its application has become more and more extensive. Nano-formulation has exerted certain advantages in the drug development based on transporters, and is also involved in the combination of targeted transporters. This review focuses on the application of novel nano-agents targeting transporters and the introduction of drug-transporter-based nano-formulations.
近年来,临床上多重耐药现象的不断出现使得人们更加关注转运体。转运体表达和活性的改变会导致药物药代动力学和药效学发生相应变化。由转运体引起的药物相互作用(DDI)会严重影响药物疗效和毒性。在药物制剂研发过程中,人们越来越关注转运体在药物作用中的影响及调控。为提高药物的靶向性和理化性质,靶向制剂的发展十分迅速。其中,新型纳米制剂表现最佳。随着纳米制剂的不断创新发展,其应用越来越广泛。纳米制剂在基于转运体的药物研发中发挥了一定优势,还参与了靶向转运体的联合应用。本综述重点关注新型靶向转运体纳米制剂的应用以及基于药物-转运体的纳米制剂介绍。